Clinical Trials Directory

Trials / Unknown

UnknownNCT04887012

Clinical Study of HLA Haploidentical CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL

Status
Unknown
Phase
Phase 1
Study type
Interventional
Enrollment
25 (estimated)
Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University · Academic / Other
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

To study the safety and effectiveness of HLA haploidentical CAR-NK cells targeting CD19 in patients with B-cell non-Hodgkin's lymphoma

Conditions

Interventions

TypeNameDescription
BIOLOGICALanti-CD19 CAR-NKlentiviral vector-transducted HLA haploidentical NK cells to express anti-CD19 CAR

Timeline

Start date
2021-05-01
Primary completion
2022-05-01
Completion
2024-05-01
First posted
2021-05-14
Last updated
2021-05-14

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT04887012. Inclusion in this directory is not an endorsement.

Clinical Study of HLA Haploidentical CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL (NCT04887012) · Clinical Trials Directory